H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Flex Pharma (NASDAQ: FLKS) today and set a price target of $40. The company’s shares closed yesterday at $4.42.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.4% and a 48.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Strongbridge Biopharma Plc, and Cyclacel Pharmaceuticals.
Flex Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $17.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.98 and a one-year low of $2.68. Currently, Flex Pharma has an average volume of 87.17K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flex Pharma, Inc. operates as a biotechnology company. It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company operates through two segments: Consumer Operations and Drug Development.